{"summary": "Author argues EXEL is a short because the FDA fully approved a Handa cabozantinib generic that Wall Street has not yet priced in due to Taiwanese-only disclosure.", "reason": "Author provides a specific asset, directional thesis, and fundamental catalyst regarding generic drug approval.", "ideas": [{"symbol": "EXEL", "direction": "short", "thesis": "Author claims Exelixis derives nearly all revenue (~$2B/yr) from cabozantinib (CABOMETYX) and that the FDA granted full approval to a Handa generic on 9/3, clearing it to sell in the US immediately. He argues EXEL quietly withdrew its Delaware patent suit against Handa on 8/31 and its FDA citizen petition failed, so the ~20% rally on 'patent protection until 2030' headlines is wrong. The catalyst is Wall Street recognizing the generic launch, likely within days, since the news was only published in Taiwan with no English coverage; main risk is that the market has already priced it in or the generic launch is delayed.", "thesis_short": "EXEL short on unpriced Handa generic approval", "quote": "The key is: I think Wall St has genuinely not yet put two and two together, that this company's main source of revenue just got handed a major L by a cheaper generic, likely launching within days.", "confidence": 0.8, "sentiment": -0.8, "timeframe": "days"}], "model": "gemini-3.1-flash-lite", "verified": true, "extraction_model": "deepseek-v4-flash"}
This Reddit post, published September 09, 2026, features u/Biostatrat discussing EXEL. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Biostatrat · Tickers: EXEL